|

Alzheimer's Disease Clinical Trials in New York, NY

55 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPhase 3<1 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)Phase 2<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3<1 mi
Reduce Loneliness in Care Partners of Persons With AD/ADRDN/A<1 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 3<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3N/A<1 mi
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's DiseasePhase 2<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol—<1 mi
Evaluating the Efficacy of the Pain Identification and Communication ToolkitN/A<1 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)—<1 mi
Genetic Studies of Early-onset Dementia—<1 mi
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults StudyN/A<1 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3<1 mi
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's DiseasePhase 2<1 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3<1 mi
Early Age-Related Hearing Loss Investigation (EARHLI)N/A<1 mi
Dementia Caregivers' Link to Assistance and ResourcesN/A<1 mi
Aβ Dynamics in LLMDPhase 4<1 mi
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease PatientsN/A<1 mi
Innate Immunity Stimulation Via TLR9 in Early ADPhase 1<1 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseN/A<1 mi
Late Onset Alzheimer's Disease—<1 mi
Triage Survey for Neurology Research Eligibility—<1 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 3<1 mi
Dominantly Inherited Alzheimer Network (DIAN)—<1 mi
Autoimmune Features of Neurodegenerative Disorders—<1 mi
NYSCF Scientific Discovery Biobank—<1 mi
Clinical Trial on Agitation in Alzheimer's DementiaPhase 25 mi
Exercise to Improve Brain Health in Older African AmericansPhase 29 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 29 mi
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease—11 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 311 mi
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/312 mi
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's DiseaseN/A12 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 313 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)—13 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 213 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Phase 313 mi
Open-label Extension Study in Participants With Early Alzheimer's DiseasePhase 213 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 316 mi
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)N/A16 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 316 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 316 mi
A BCT Intervention for an Hourly Activity Habit Among Caregivers for Persons With AD/ADRDN/A17 mi
BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRDN/A17 mi
Tau Networks in Psychotic Alzheimer&#39;s Disease—17 mi
Studies of Brain and Body Interaction—25 mi
A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage ADN/A26 mi
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older AdultsPhase 228 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPhase 229 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePhase 334 mi
Neurologic Stem Cell Treatment StudyN/A45 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.